ARCH PATHOL LAB MED:细胞病理医师超声引导下细针穿刺与病理医师触诊引导下细针穿刺的比较

2018-10-30 MedSci MedSci原创

虽然病理学家已经建立细针穿刺(FNA),但它主要是通过手工触诊进行的。近年来,病理学家开始涉足超声引导FNAs (UGFNAs)。关于病理学家使用这种相对较新技术的经验的报告显示前景较好。然而,迄今为止,文献中很少有研究将病理学家进行的UGFNA与传统的病理学家进行触诊引导的FNA (PGFNA)进行比较。本研究的目的就是通过一个学术医学中心的细胞病理学家将UGFNA与PGFNA进行比较。由加州大

虽然病理学家已经建立细针穿刺(FNA),但它主要是通过手工触诊进行的。近年来,病理学家开始涉足超声引导FNAs (UGFNAs)。关于病理学家使用这种相对较新技术的经验的报告显示前景较好。然而,迄今为止,文献中很少有研究将病理学家进行的UGFNA与传统的病理学家进行触诊引导的FNA (PGFNA)进行比较。本研究的目的就是通过一个学术医学中心的细胞病理学家将UGFNA与PGFNA进行比较。
由加州大学洛杉矶分校病理学系FNA诊所的细胞病理学家进行的FNAs回顾性研究。收集包括性能技术(UGFNA与PGFNA)、病变部位和大小、充分性(非诊断率)和每次手术的通过率等数据。并与FNA结果进行比较。比较UGFNA和PGFNA病例的差异。
在研究期间的1029例FNA病例中包括UGFNA病例449例(43.6%),PGFNA病例580例(56.4%)。UGFNA和PGFNA的非诊断率分别为6.7%(449例中30例)和20.7%(580例中120例)。与PGFNA相比,UGFNA对甲状腺内病变(6.0%比33.3%)、头颈部病变(6.6%比21.2%)、唾液腺病变(6.2%比17.1%)以及所有结节大小的非诊断率也显著降低。1029例FNA患者中495例(48.1%)开展随访。与PGFNA相比,UGFNA的不一致率显著降低(5.4%对12.8%)。
本研究显示细胞病理学家操作的UGFNA与PGFNA相比有更好的表现特征。
原始出处:
本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786207, encodeId=b0f81e8620727, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 05 16:10:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769806, encodeId=415b1e69806c2, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Sep 09 07:10:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805359, encodeId=937318053596b, content=<a href='/topic/show?id=7602e7975da' target=_blank style='color:#2F92EE;'>#细胞病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77975, encryptionId=7602e7975da, topicName=细胞病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 11 00:10:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813457, encodeId=f3b9181345e1f, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 15 15:10:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311924, encodeId=29c4131192491, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609258, encodeId=e37f16092581b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-08-05 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786207, encodeId=b0f81e8620727, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 05 16:10:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769806, encodeId=415b1e69806c2, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Sep 09 07:10:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805359, encodeId=937318053596b, content=<a href='/topic/show?id=7602e7975da' target=_blank style='color:#2F92EE;'>#细胞病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77975, encryptionId=7602e7975da, topicName=细胞病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 11 00:10:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813457, encodeId=f3b9181345e1f, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 15 15:10:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311924, encodeId=29c4131192491, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609258, encodeId=e37f16092581b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786207, encodeId=b0f81e8620727, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 05 16:10:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769806, encodeId=415b1e69806c2, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Sep 09 07:10:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805359, encodeId=937318053596b, content=<a href='/topic/show?id=7602e7975da' target=_blank style='color:#2F92EE;'>#细胞病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77975, encryptionId=7602e7975da, topicName=细胞病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 11 00:10:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813457, encodeId=f3b9181345e1f, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 15 15:10:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311924, encodeId=29c4131192491, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609258, encodeId=e37f16092581b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786207, encodeId=b0f81e8620727, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 05 16:10:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769806, encodeId=415b1e69806c2, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Sep 09 07:10:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805359, encodeId=937318053596b, content=<a href='/topic/show?id=7602e7975da' target=_blank style='color:#2F92EE;'>#细胞病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77975, encryptionId=7602e7975da, topicName=细胞病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 11 00:10:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813457, encodeId=f3b9181345e1f, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 15 15:10:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311924, encodeId=29c4131192491, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609258, encodeId=e37f16092581b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786207, encodeId=b0f81e8620727, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 05 16:10:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769806, encodeId=415b1e69806c2, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Sep 09 07:10:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805359, encodeId=937318053596b, content=<a href='/topic/show?id=7602e7975da' target=_blank style='color:#2F92EE;'>#细胞病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77975, encryptionId=7602e7975da, topicName=细胞病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 11 00:10:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813457, encodeId=f3b9181345e1f, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 15 15:10:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311924, encodeId=29c4131192491, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609258, encodeId=e37f16092581b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 rgjl
  6. [GetPortalCommentsPageByObjectIdResponse(id=1786207, encodeId=b0f81e8620727, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 05 16:10:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769806, encodeId=415b1e69806c2, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Sep 09 07:10:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805359, encodeId=937318053596b, content=<a href='/topic/show?id=7602e7975da' target=_blank style='color:#2F92EE;'>#细胞病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77975, encryptionId=7602e7975da, topicName=细胞病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Apr 11 00:10:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813457, encodeId=f3b9181345e1f, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 15 15:10:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311924, encodeId=29c4131192491, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609258, encodeId=e37f16092581b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 03:10:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]

相关资讯

Radiology:肺结节横行的年代,选哪种穿刺技术好呢?

本研究旨在比较电磁导航支气管镜(ENB)引导和CT引导下穿刺肺结节组织取样的诊断价值及并发症发生率,并将结果发表在Radiology上。

“早期穿刺”人工血管,重新建立尿毒症患者血管通路

尿毒症是一个全球关注的公共卫生问题,目前上海每年就有2万名左右的患者在接受维持性血液透析治疗,良好的血管通路是保障充分血液透析的前提。由于种种原因,长期透析的患者往往会出现血管通路恶化的现象,而如今,仁济医院血管外科与肾脏内科用血透通路新技术——“早期穿刺”人工血管,重新建立尿毒症患者“生命线”。目前临床已经完成20例,效果良好。56岁的刘先生因慢性肾功能衰竭,已到终末期,内环境紊乱,消化道症状

股静脉穿刺导丝滞留陷窝韧带与耻骨肌之间一例

患者,男,52岁。因“发热伴神志不清4h余”于2016年6月23日来我院就诊

郑州一医院被指将右肺穿刺手术做成左肺,涉事医生已被停职

郑州大学第一附属医院将一名患者的右肺穿刺手术做成左肺后,其家人提出十万元的赔偿要求。10月17日,医院方面回应记者称,已将涉事医生停职,等待下一步处理。目前,双方仍未就赔偿方案达成一致意见。穿刺手术做反,患方提出十万元赔偿张娜(化名)称,其母亲今年9月30日因肺炎住进郑州大学第一附属医院(以下简称“郑大一附院”)。经检查,医生提出对右肺一结节处做穿刺手术,检查该结节是良性还是恶性。张娜给记者提供

这样的气胸不少见,胸腔穿刺需谨慎!

居然还有慢性气胸,你是在逗我么?

如何减少穿刺后出现的淤青?

静脉输液是护士在日常工作中最基本护理操作,静脉输液后针眼周围的局部组织经常会出现淤青的现象,这种情况会为患者带来不必要的痛苦,也会为我们护士在再次给患者静脉穿刺带来难度。